Research across Pneumonia
Related studies from across the Pneumonia family.
21 trials tracked for bacterial pneumonia: 11 in phase 3 or 4 and 3 with published results. The most-cited published study has 232 citations.
Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several agents have been evaluated for the treatment of bacterial pneumonia. Imipenem demonstrated a significant reduction in all-cause mortality at day 28 compared to the comparator (15.9% vs. 21.3%, p<0.001) and a significantly higher rate of favorable clinical response at early follow-up (61.0% vs. 55.8%, p<0.001) 3. Omadacycline showed high rates of clinical response, with approximately 87.7% to 95.9% of patients achieving an investigator's assessment of clinical response at various evaluation points 5.
Other established interventions include Ceftaroline [1, 8, 9], Omadacycline 2, ampicillin sodium/sulbactam sodium 7, Telavancin [10, 11], and Nemonoxacin 6. While Nemonoxacin was evaluated for clinical success and infection relapse, the results did not reach statistical significance (p=0.08 and p=0.154, respectively) 6.
Amikacin inhalation solution was evaluated in a trial where no statistically significant differences were found between treatment arms regarding survival, pneumonia-related death, or early clinical response 4.
AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Pneumonia family.